Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies
NCT04033302Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of CD7 CAR-T cell therapy in t-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LBL), acute myeloid leukemia (AML), natural killer cell lymphoma (NKCL), sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
CD7 CAR-T cell therapy
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell acute lymphoblastic lymphoma (T-LBL)acute myeloid leukemia (AML)natural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT04033302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033302.